financetom
Business
financetom
/
Business
/
IDFC appoints Mahendra Shah as MD & CEO effective from October 1
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IDFC appoints Mahendra Shah as MD & CEO effective from October 1
Aug 24, 2022 8:29 AM

Private lender IDFC on on August 24 said it has appointed Mahendra Shah as managing director and chief executive officer with effect from October 1, 2022, till September 30, 2023, subject to the approval of the shareholders.

Share Market Live

NSE

Shah will replace incumbent MD and CEO Sunil Kakar, whose term will end on September 30, 2022, the company said in an exchange filing.

Shah was the group company secretary and group compliance officer of IDFC FIRST Bank Ltd and has been the group head — governance, compliance and secretarial and senior advisor — taxation at IDFC Ltd for more than a decade.

Also Read: After selling tickets worth Rs 300 cr in 10 days, EaseMyTrip says 'pent-up demand yet to kick in'

Currently, he is company secretary and compliance officer at IDFC Ltd since May 24, 2019. In this role, Shah has been responsible for secretarial, governance, and compliance function for over 26 companies/entities of IDFC Group.

Prior to joining IDFC in 2001, Shah worked with International Paper Ltd for a period of six years as director of finance and company secretary, where he was in charge of the finance function and regulatory compliances.

Shah has worked as head of taxation in SKF Bearings India Ltd where he was responsible for direct and indirect taxation matters across India. He also worked for a short period with Pfizer Ltd as a finance officer.

Also Read: Twitter whistleblower: Spies for foreign agencies are on social media company's payroll

He completed his article-ship for CA with Bansi S. Mehta & Co, where he spent three years. Also, he is a qualified member of the Institute of Chartered Accountants of India (ICAI), the Institute of Cost & Management Accountants of India (ICWA), and the Institute of Company Secretaries of India (ICSI).

(Edited by : Shoma Bhattacharjee)

First Published:Aug 24, 2022 5:29 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--AbbVie to Acquire Aliada Therapeutics for $1.4 Billion in Cash
--AbbVie to Acquire Aliada Therapeutics for $1.4 Billion in Cash
Oct 28, 2024
08:12 AM EDT, 10/28/2024 (MT Newswires) -- Price: 188.04, Change: +0.19, Percent Change: +0.10 ...
Mitsubishi UFG Previews This Week's UK Budget
Mitsubishi UFG Previews This Week's UK Budget
Oct 28, 2024
08:12 AM EDT, 10/28/2024 (MT Newswires) -- One of the main focuses this week will be the release of the much anticipated United Kingdom Budget from the new Labour government, said MUFG. It has been reported that the government is seeking to fill a fiscal hole of around 20 billion pounds and may implement additional tightening measures to give it...
Brunswick Insider Sold Shares Worth $380,264, According to a Recent SEC Filing
Brunswick Insider Sold Shares Worth $380,264, According to a Recent SEC Filing
Oct 28, 2024
11:09 AM EDT, 10/28/2024 (MT Newswires) -- Joseph W McClanathan, Director, on Oct. 25, 2024, sold 4,745 shares in Brunswick (BC) for $380,264. Following the Form 4 filing with the SEC, McClanathan has control over a total of 19,218 shares of the company, with 19,218 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/14930/000001493024000153/xslF345X05/wk-form4_1730127819.xml Price: 82.09, Change: +1.33, Percent Change: +1.65 ...
MEI Pharma Shares Gain on Sale of Drug Asset ME-344
MEI Pharma Shares Gain on Sale of Drug Asset ME-344
Oct 28, 2024
12:43 PM EDT, 10/28/2024 (MT Newswires) -- MEI Pharma ( MEIP ) shares gained more than 8% after the company said Friday it had sold the rights to drug asset ME-344. The company said in a securities filing that it had entered an agreement with Aardvark Therapeutics to sell virtually all of the rights to ME-344 for an initial payment...
Copyright 2023-2026 - www.financetom.com All Rights Reserved